Send the following on WhatsApp
Continue to ChatCarfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison - https://avesis.ankara.edu.tr/yayin/64cdd48c-702e-4a09-a84e-0fccc3a2cd41/carfilzomib-daratumumab-and-dexamethasone-kdd-vs-lenalidomide-sparing-pomalidomide-containing-triplet-regimens-for-relapsed-refractory-multiple-myeloma-an-indirect-treatment-comparison